AbbVie Inc. (ABBV) Stock Analysis — Probabli.AI
AI-powered analysis for ABBV (AbbVie Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
← Healthcare Stocks
Last price: $198.14 · Market cap: $355.4B · AI outlook: Bullish
AbbVie Inc. commands a strong position in the pharmaceutical sector, underpinned by its innovative drug portfolio and robust cash flow generation. Despite challenges such as competition from biosimilars and high payout ratios, its strategic initiatives, including acquisitions and pipeline expansion, paint a favorable outlook. Investor confidence is buoyed by a positive analyst consensus and a…
Probabilistic 1-Year Outlook
- Bull 45% · Neutral 35% · Bear 20%
- 1-year price estimates — P10: $175 / P50: $210 / P90: $260
- AbbVie has strong fundamentals supported by a robust product line, attractive dividend yield, and consensus buy recommendations from analysts. However, potential competitive pressures, including biosimilars and patent…
5-Year Outlook
- Bull 50% · Neutral 30% · Bear 20%
- 5-year price estimates — P10: $140 / P50: $290 / P90: $400
SWOT Highlights
- Strength: Robust product portfolio
- Strength: Strong brand reputation
- Risk: High dependency on certain core products
- Risk: Patent expiration risks
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
18 Wall Street analysts rate ABBV a BUY with a mean price target of $253.71. AbbVie Inc. currently pays a dividend with a yield of approximately 3.48%.
Last analyzed · Model: gpt-4o. How this forecast works · Accuracy & validation.
ABBV forecast details · ABBV sentiment details
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.